Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 56Triple Negative Breast Neoplasms 14Sarcoma 7Neoplasm Metastasis 6Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Prostatic Neoplasms 2Inflammatory Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Liposarcoma 1Leiomyosarcoma 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1

Interventions

Ifosfamide 15Methotrexate 12Doxorubicin 12Filgrastim 10Cisplatin 10Cyclophosphamide 9Etoposide 8Gemcitabine 7cabozantinib 6apatinib 6Magnetic Resonance Spectroscopy 6Leucovorin 6X-Rays 5Specimen Handling 5Sirolimus 5Phantoms, Imaging 5Nivolumab 5Neoadjuvant Therapy 5camrelizumab 4Vincristine 4Topotecan 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Drug Therapy 4Docetaxel 4Biopsy 4regorafenib 3palbociclib 3olaparib 3mifamurtide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Osteosarcoma × eribulin × Clear all
NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡